Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI – Get Free Report) have been given a consensus recommendation of “Buy” by the six analysts that are covering the company, MarketBeat reports.

Q4 2024 Earnings Call Transcript March 31, 2025 Rani Therapeutics Holdings, Inc. misses on earnings expectations. Reported ...

Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® ...

In a report released today, Annabel Samimy from Stifel Nicolaus maintained a Buy rating on Rani Therapeutics Holdings (RANI – Research Report), ...

Despite a significant decrease in cash reserves, Rani Therapeutics Holdings Inc (RANI) focuses on advancing its promising RaniPill technology and strategic programs.

March 31, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial ...

Talat Imran; Chief Executive Officer, Director; Rani Therapeutics Holdings Inc Svai Sanford; Chief Financial Officer; Rani Therapeutics Holdings Inc Welcome to the Rani fourth-quarter and full ...

March 31, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of ...

Please go ahead. Thank you, Operator. Please turn to Slide 2. Joining us on the call today from Rani Therapeutics are Chief Executive Officer, Talat Imran; and Chief Financial Officer, Svai Sanford.